Beijing Tong Ren Tang Chinese Medicine Company Limited

Informe acción SEHK:3613

Capitalización de mercado: HK$8.5b

Beijing Tong Ren Tang Chinese Medicine Dirección

Dirección controles de criterios 2/4

El CEO de Beijing Tong Ren Tang Chinese Medicine's es Fei Chen , nombrado en Mar 2024, tiene una permanencia de menos de un año. compensación anual total es HK$2.18M, compuesta por 60.8% salario y 39.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.005% de las acciones de la empresa, por valor de HK$390.68K. La antigüedad media del equipo directivo y de la junta directiva es de 0.3 años y 2.9 años, respectivamente.

Información clave

Fei Chen

Chief Executive Officer (CEO)

HK$975.0k

Compensación total

Porcentaje del salario del CEO65.1%
Permanencia del CEOless than a year
Participación del CEO0.005%
Permanencia media de la direcciónless than a year
Promedio de permanencia en la Junta Directiva3yrs

Actualizaciones recientes de la dirección

Recent updates

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Feb 05
Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) 28% Share Price Plunge Could Signal Some Risk

Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Jan 03
Calculating The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Sep 28
A Look At The Intrinsic Value Of Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613)

Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Jul 12
Here's Why We Think Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Might Deserve Your Attention Today

Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Mar 29
Is Now The Time To Put Beijing Tong Ren Tang Chinese Medicine (HKG:3613) On Your Watchlist?

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Apr 28
Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Has Announced That It Will Be Increasing Its Dividend To HK$0.28

Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Mar 25
Beijing Tong Ren Tang Chinese Medicine (HKG:3613) Will Pay A Larger Dividend Than Last Year At HK$0.28

Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?

Oct 27
Are Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Investors Paying Above The Intrinsic Value?

Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 28
Beijing Tong Ren Tang Chinese Medicine's (HKG:3613) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Mar 11
Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Feb 04
What Type Of Returns Would Beijing Tong Ren Tang Chinese Medicine's(HKG:3613) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?

Jan 18
Should Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Be Part Of Your Dividend Portfolio?

Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?

Dec 29
Could The Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Ownership Structure Tell Us Something Useful?

Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Dec 11
Read This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares

Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Nov 23
Beijing Tong Ren Tang Chinese Medicine Company Limited's (HKG:3613) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Fei Chen en comparación con los beneficios de Beijing Tong Ren Tang Chinese Medicine?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2023HK$975kHK$635k

HK$540m

Sep 30 2023n/an/a

HK$619m

Jun 30 2023n/an/a

HK$697m

Mar 31 2023n/an/a

HK$672m

Dec 31 2022HK$2mHK$1m

HK$646m

Sep 30 2022n/an/a

HK$601m

Jun 30 2022n/an/a

HK$555m

Mar 31 2022n/an/a

HK$582m

Dec 31 2021HK$1mHK$1m

HK$608m

Compensación vs. Mercado: La compensación total de Fei($USD277.68K) está por debajo de la media de empresas de tamaño similar en el mercado Hong Kong ($USD522.29K).

Compensación vs. Ingresos: La compensación de Fei ha sido consistente con los resultados de la empresa en el último año.


CEO

Fei Chen (52 yo)

less than a year

Permanencia

HK$975,000

Compensación

Mr. Fei Chen serves as Acting Chief Executive Officer of Beijing Tong Ren Tang Chinese Medicine Company Limited since March 28, 2024. She serves as Executive Director and until April 19, 2023 served as Chi...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Hai Ou Gu
Executive Chairman of the Boardless than a yearsin datossin datos
Fei Chen
Acting CEOless than a yearHK$975.00k0.0051%
HK$ 437.2k
Fung Yi Tsang
CFO & Company Secretary4yrssin datossin datos
Zheng Guo Shen
Deputy GM & General Counselno datasin datossin datos

0.4yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 3613 no se considera experimentado ( 0.3 años antigüedad media), lo que sugiere un nuevo equipo.


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Hai Ou Gu
Executive Chairman of the Boardless than a yearsin datossin datos
Fei Chen
Acting CEO4.2yrsHK$975.00k0.0051%
HK$ 437.2k
Yok-Sing Tsang
Independent Non-Executive Director6.7yrsHK$288.00ksin datos
Ngai Chi Chan
Independent Non-Executive Director11.1yrsHK$288.00ksin datos
Li Feng
Non-Executive Director1.8yrssin datossin datos
Hong Xi Xu
Independent Non-Executive Director1.2yrsHK$240.00ksin datos

3.0yrs

Permanencia media

54.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 3613 no se considera experimentada (2.9 años de permanencia promedio), lo que sugiere una nueva junta directiva.